课题基金 / 基金详情

Clinical study for target control infusion system with processed EEG

Clinical study for target control infusion system with processed EEG
脑电图处理靶控输注系统临床研究
批准号:
08457398
负责人:
MATSUKI Akitomo
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1997

项目摘要

项目成果

MATSUKI Akitomo的其他基金

相似基金

相关文献

中文摘要
翻译
催眠终点和/或处理的EEG变量,例如,研究了脑电双频指数(BIS)、95%边缘频率(95%SEF)和中值频率(MF)在全静脉(i. v.)麻醉。本研究比较了异丙酚催眠时对口头命令无反应(UVC)、睫毛反射消失(LER)和机械鼻膜刺激的体动反应(NBMR)与BIS、95%SEF和MF的关系。[)芬太尼静脉麻醉。42例患者随机分为两组:异丙酚组(30 mg kg<@D1 - 1@> D1 h <@D1-1@>D1)和异丙酚组(30 mg kg<@D1 - 1 @> D1 h <@D1 - 1 @>D1+芬太尼2 μ g kg<@D1-1@>D1)。(PE,n=20)。在UVC、LER和NBMR抑制(INBMR)时监测并记录BIS、95%SEF、MF和丙泊酚剂量。PF组的BIS值显著高于P组,即,74.7(]SY. ±. [)10.9,73.1()SY. ±. [)10.5和47.1(]SY. ±. [)9.2 vs.65.8(]SY. ±. [)9.8,59.6(±)SY. [)10和33.8(]SY ±. [)5.7在UVC,LER和INBMR。与P组相比,PF组达到催眠终点所需的丙泊酚剂量显著降低。与P组相比,PF组在INBMR时的血浆丙泊酚浓度较低(9.2(± SD))。[)2.0 1 μ g ml<@D1-1@>D1 ys.14.1(]SY. ±. [)4.2 μ g ml<@D1-1@>D1)。我们的研究结果表明,芬太尼预处理增强丙泊酚的作用,并在较高的BIS值和较低的丙泊酚剂量和浓度(在INBMR测量)下达到催眠终点,BIS依赖于监测麻醉深度的麻醉方案。
英文摘要
Hypnotic endpoints and/or processed EEG variables, e.g., bispectral index (BIS), 95% spectral edge frequency (95%SEF)and median frequency (MF) have been studied to monitor anaessthetic (hypnosis) depth during total intravenous (i.v.) anaesthesia. In this study, the relationship between the hypnotic endpoints of unresponsiveness to verbal commands (UVC), loss of eyelash reflex (LER) and body movement response to mechanical nasal membrane stimulation (abbreviated as NBMR) vs. BIS,95% SEF and MF during propofol(]SY.+-。[)fentanyl i.v.anaesthesia is presented. Forty-two patients were randomly assigned to receive either propofol infusion, 30 mg kg<@D1-1@>D1h<@D1-1@>D1 (P,n=22) or propofol infusion, 30 mg kg<@D1-1@>D1h<@D1-1@>D1+fentanyl bolus, 2mug kg<@D1-1@>D1 iv. (PE,n=20). BIS,95% SEF and MF and propofol doses were monitored and recorded at UVC,LER and inhibition of NBMR (INBMR). The BIS values were significantly higher in the PF as compared to the P group, i.e., 74.7(]SY.+-。[)10.9,73.1(]SY.+-。[)10.5 and 47.1(]SY.+-。[)9.2 vs.65.8(]SY.+-。[)9.8,59.6(]SY.+-。[)10 and 33.8(]SY.+-。[)5.7 at UVC,LER and INBMR,respectively. Doses of propofol for achieving the hypnotic endpoints were significantly lower in the PF group as comparedto the P group. Plasma propofol concentrations at INBMR were lower in the PF as compared to the P group (9.2(]SY.+-。[)2.0 mug ml<@D1-1@>D1 ys.14.1(]SY.+-。[)4.2mug ml<@D1-1@>D1). Our results suggest that fentanyl pretreatment potentiates the effects of propofol and achieves the hypnotic endpoints at higher BIS values and lower propofoldoses and concentrations (measured at INBMR) and that the BIS is dependent on the anaesthetic regimen for monitoring the depth of anaesthesia.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
坂井哲博: "プロポフォール、フェンタニル、ケタミンを用いた全静脈麻酔を行い、麻酔薬の薬物動態を追跡できた乳児症例" 麻酔. 47・3. 314-317 (1998)
Tetsuhiro Sakai:“使用丙泊酚、芬太尼和氯胺酮进行全静脉麻醉的婴儿病例,可以追踪麻醉药的药代动力学”47·3(1998)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
WD Mi, et al: "Haemodynamic and electroencephalograph responses to intubation during induction with propofol orpropofol/fentanyl" Can J Anaesth. 45. 19-22 (1998)
WD Mi 等人:“丙泊酚或丙泊酚/芬太尼诱导期间插管的血流动力学和脑电图反应”Can J Anaesth。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 21 条
    A study on the mechanism of General Anesthesia-inuduced sleep-relation to endogenous sleep related substances
    • 批准号:
      13671560
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.41万
    • 财政年份:
      2001
    • 负责人:
      MATSUKI Akitomo
    • 依托单位:
    Pharmacokinetic study for target controlled infusion of ketamine and fentanyl
    • 批准号:
      05454412
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $2.62万
    • 财政年份:
      1993
    • 负责人:
      MATSUKI Akitomo
    • 依托单位:
    国内基金
    海外基金
    mPFC-VTA-NAc多巴胺能投射调控丙泊酚麻醉—觉醒的机制研究
    • 批准号:
      82371284
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      许涛
    • 依托单位: